PureTech Health (LON:PRTC) had its price target boosted by Liberum Capital from GBX 450 ($5.54) to GBX 490 ($6.03) in a report issued on Wednesday morning, Stock Target Advisor reports. Liberum Capital currently has a buy rating on the stock.
Other equities research analysts also recently issued reports about the stock. Peel Hunt reiterated a buy rating and set a GBX 480 ($5.91) price target on shares of PureTech Health in a research report on Tuesday, June 2nd. Peel Hunt restated a buy rating on shares of PureTech Health in a research report on Wednesday, July 8th.
PRTC stock opened at GBX 272 ($3.35) on Wednesday. The firm has a 50 day moving average of GBX 272.93 and a 200-day moving average of GBX 269.86. PureTech Health has a 12-month low of GBX 2.11 ($0.03) and a 12-month high of GBX 339.36 ($4.18). The company has a current ratio of 1.21, a quick ratio of 1.18 and a debt-to-equity ratio of 6.04. The company has a market cap of $776.59 million and a price-to-earnings ratio of 1.88.
In related news, insider John LaMattina acquired 8,201 shares of the business’s stock in a transaction that occurred on Monday, May 18th. The stock was purchased at an average cost of GBX 246 ($3.03) per share, for a total transaction of £20,174.46 ($24,827.05). Insiders have purchased a total of 15,601 shares of company stock valued at $3,845,046 over the last 90 days.
PureTech Health Company Profile
PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.
See Also: What is Call Option Volume?
Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.